This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Badawi, A. F. Articles by Kadlubar, F. F. Search for Related Content PubMed PubMed Citation Articles by Badawi, A. F. Articles by Kadlubar, F. F.

Role of Aromatic Amine Acetyltransferases, NAT1 and NAT2, in Carcinogen-DNA Adduct Formation in the Human Urinary Bladder

Division of Molecular Epidemiology (HFT-100), National Center for Toxicological Research, Jefferson, Arkansas 72079 [A. F. B., F. F. K.]; Laboratory of Biochemical Risk Analysis, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709 [A. H., D. A. B.]; University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 [N. P. L.]

The metabolic activation and detoxification pathways associated with the carcinogenic aromatic amines provide an extraordinary model of polymorphisms that can modulate human urinary bladder carcinogenesis. In this study, the metabolic N-acetylation of p-aminobenzoic acid (PABA) to N-acetyl-PABA (NAT1 activity) and of sulfamethazine (SMZ) to N-acetyl-SMZ (NAT2 activity), as well as the O-acetylation of N-hydroxy-4-aminobiphenyl (OAT activity; catalyzed by NAT1 and NAT2), were measured in tissue cytosols prepared from 26 different human bladder samples; then DNA was isolated for determination of NAT1 and NAT2 genotype and for analyses of carcinogen-DNA adducts.

Both PABA and OAT activities were detected, with mean activities ± SD of 2.9 ± 2.3 nmol/min/mg protein and 1.4 ± 0.7 pmol bound/mg DNA/min/mg protein, respectively. However, SMZ activities were below the assay limits of detection (<10 pmol/min/mg protein). The levels of putative carcinogen-DNA adducts were quantified by ³²P-postlabeling and averaged 2.34 ± 2.09 adducts/10⁸ deoxyribonucleotide phosphate (dNp). Moreover, the DNA adduct levels in these tissues correlated with their NAT1-dependent PABA activities (r = 0.52; P < 0.01) but not with their OAT activities. Statistical and probit analyses indicated that this NAT1 activity was not normally distributed and appeared bimodal. Applying the NAT1:OAT activity ratios (N:O ratio) allowed arbitrary designation of rapid and slow NAT1 phenotypes, with a cutpoint near the median value. Within each of these subgroups, NAT1 correlated with OAT (P < 0.05); DNA adduct levels were elevated 2-fold in individuals with the rapid NAT1 or NAT1/OAT phenotype.

Examination of DNA sequence polymorphisms in the NAT1 gene by PCR have demonstrated that an NAT1 polyadenylation polymorphism is associated with differences in tissue NAT1 enzyme activity; accordingly, NAT1 activity in the bladder of individuals with the heterozygous NAT1*10 allele was 2-fold higher than in subjects homozygous for the putative wild-type NAT1*4 allele. Likewise, DNA adduct levels in the mucosa of the urinary bladder were found to be 2-fold (P < 0.05) higher in individuals with the heterozygous NAT1*10 allele (3.5 ± 2.1 adducts/10⁸ dNp) as compared to NAT1*4 homozygous (1.8 ± 1.9 adducts/10⁸ dNp). Thus, these data provide strong support for the hypothesis that NAT1 activity in the urinary bladder mucosa represents a major bioactivation step that converts urinary N-hydroxy arylamines to reactive N-acetoxy esters that form covalent DNA adducts.

Since previous studies have indicated that hepatic NAT2 activity is an important detoxification step for bladder carcinogenesis, one would predict that individuals who inherit slow NAT2 and rapid NAT1 (NAT1*10) genotypes would be at highest risk. Although our sample size was limited, this combined genotype indeed exhibited the highest adduct level (4.2 ± 1.6 adducts/10⁸ dNp) and the highest NAT1 activity (5.8 ± 2.5 nmol/min/mg protein) among all other combined NAT1-NAT2 genotypes. Together, these data provide the first evidence that phenotypic and genotypic polymorphisms in both NAT1 and NAT2 are predictive of DNA adduct levels in human urinary bladder.

¹ Current address: Nutritional Sciences, Faculty of Medicine, University of Toronto, 150 College, Toronto, Ontario, Canada M5S 1A8.

² To whom requests for reprints should be addressed.

Received 7/12/95. Accepted 10/ 5/95.

This article has been cited by other articles:

				E. Taioli Gene-environment interaction in tobacco-related cancers Carcinogenesis, August 1, 2008; 29(8): 1467 - 1474. [Abstract] [Full Text] [PDF]

				J.-M. Yuan, K. K. Chan, G. A. Coetzee, J.E. Castelao, M. A. Watson, D. A. Bell, R. Wang, and M. C. Yu Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer Carcinogenesis, July 1, 2008; 29(7): 1386 - 1393. [Abstract] [Full Text] [PDF]

				N. Ragunathan, J. Dairou, B. Pluvinage, M. Martins, E. Petit, N. Janel, J.-M. Dupret, and F. Rodrigues-Lima Identification of the Xenobiotic-Metabolizing Enzyme Arylamine N-Acetyltransferase 1 as a New Target of Cisplatin in Breast Cancer Cells: Molecular and Cellular Mechanisms of Inhibition Mol. Pharmacol., June 1, 2008; 73(6): 1761 - 1768. [Abstract] [Full Text] [PDF]

				L. Jiao, M. A. Doll, D. W. Hein, M. L. Bondy, M. M. Hassan, J. E. Hixson, J. L. Abbruzzese, and D. Li Haplotype of N-Acetyltransferase 1 and 2 and Risk of Pancreatic Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2379 - 2386. [Abstract] [Full Text] [PDF]

				S. Sanderson, G. Salanti, and J. Higgins Joint Effects of the N-Acetyltransferase 1 and 2 (NAT1 and NAT2) Genes and Smoking on Bladder Carcinogenesis: A Literature-based Systematic HuGE Review and Evidence Synthesis Am. J. Epidemiol., October 1, 2007; 166(7): 741 - 751. [Abstract] [Full Text] [PDF]

				K. Broberg, J. Bjork, K. Paulsson, M. Hoglund, and M. Albin Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer Carcinogenesis, July 1, 2005; 26(7): 1263 - 1271. [Abstract] [Full Text] [PDF]

				L. R. Cantilena, A. G. Katki, R. W. Klecker, and J. M. Collins Metabolism by N-Acetyltransferase 1 In Vitro and in Healthy Volunteers: A Prototype for Targeted Inhibition J. Clin. Pharmacol., December 1, 2004; 44(12): 1405 - 1411. [Abstract] [Full Text] [PDF]

				J. Dairou, N. Atmane, F. Rodrigues-Lima, and J.-M. Dupret Peroxynitrite Irreversibly Inactivates the Human Xenobioticmetabolizing Enzyme Arylamine N-Acetyltransferase 1 (NAT1) in Human Breast Cancer Cells: A CELLULAR AND MECHANISTIC STUDY J. Biol. Chem., February 27, 2004; 279(9): 7708 - 7714. [Abstract] [Full Text] [PDF]

				J. C. Schroeder, K. Conway, Y. Li, K. Mistry, D. A. Bell, and J. A. Taylor p53 Mutations in Bladder Cancer: Evidence for Exogenous versus Endogenous Risk Factors Cancer Res., November 1, 2003; 63(21): 7530 - 7538. [Abstract] [Full Text] [PDF]

				P. J. Adam, J. Berry, J. A. Loader, K. L. Tyson, G. Craggs, P. Smith, J. De Belin, G. Steers, F. Pezzella, K. F. Sachsenmeir, et al. Arylamine N-Acetyltransferase-1 Is Highly Expressed in Breast Cancers and Conveys Enhanced Growth and Resistance to Etoposide in Vitro Mol. Cancer Res., September 1, 2003; 1(11): 826 - 835. [Abstract] [Full Text] [PDF]

				Y. Tsuneoka, T. P. Dalton, M. L. Miller, C. D. Clay, H. G. Shertzer, G. Talaska, M. Medvedovic, and D. W. Nebert 4-Aminobiphenyl-Induced Liver and Urinary Bladder DNA Adduct Formation in Cyp1a2(-/-) and Cyp1a2(+/+) Mice J Natl Cancer Inst, August 20, 2003; 95(16): 1227 - 1237. [Abstract] [Full Text] [PDF]

				G. M. Shaw, V. Nelson, D. M. Iovannisci, R. H. Finnell, and E. J. Lammer Maternal Occupational Chemical Exposures and Biotransformation Genotypes as Risk Factors for Selected Congenital Anomalies Am. J. Epidemiol., March 15, 2003; 157(6): 475 - 484. [Abstract] [Full Text] [PDF]

				M. Gago-Dominguez, D. A. Bell, M. A. Watson, J.-M. Yuan, J.E. Castelao, D. W. Hein, K. K. Chan, G. A. Coetzee, R. K. Ross, and M. C. Yu Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2 Carcinogenesis, March 1, 2003; 24(3): 483 - 489. [Abstract] [Full Text] [PDF]

				P. G. Shields Tobacco Smoking, Harm Reduction, and Biomarkers J Natl Cancer Inst, October 2, 2002; 94(19): 1435 - 1444. [Abstract] [Full Text] [PDF]

				L. Airoldi, F. Orsi, C. Magagnotti, R. Coda, D. Randone, G. Casetta, M. Peluso, A. Hautefeuille, C. Malaveille, and P. Vineis Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies Carcinogenesis, May 1, 2002; 23(5): 861 - 866. [Abstract] [Full Text] [PDF]

				M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility J. Med. Genet., April 1, 2002; 39(4): 225 - 242. [Abstract] [Full Text] [PDF]

				P. F. Firozi, M. L. Bondy, A. A. Sahin, P. Chang, F. Lukmanji, E. S. Singletary, M. M. Hassan, and D. Li Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer Carcinogenesis, February 1, 2002; 23(2): 301 - 306. [Abstract] [Full Text] [PDF]

				W. Zhou, G. Liu, S. W. Thurston, L. L. Xu, D. P. Miller, J. C. Wain, T. J. Lynch, L. Su, and D. C. Christiani Genetic Polymorphisms in N-acetyltransferase-2 and Microsomal Epoxide Hydrolase, Cumulative Cigarette Smoking, and Lung Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 15 - 21. [Abstract] [Full Text]

				S. Fronhoffs, T. Bruning, E. Ortiz-Pallardo, P. Brode, B. Koch, V. Harth, A. Sachinidis, H. M. Bolt, C. Herberhold, H. Vetter, et al. Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck Carcinogenesis, September 1, 2001; 22(9): 1405 - 1412. [Abstract] [Full Text] [PDF]

				I. Cascorbi, I. Roots, and J. Brockmoller Association of NAT1 and NAT2 Polymorphisms to Urinary Bladder Cancer: Significantly Reduced Risk in Subjects with NAT1*10 Cancer Res., July 1, 2001; 61(13): 5051 - 5056. [Abstract] [Full Text] [PDF]

				D. W. Hein, C. A. McQueen, D. M. Grant, G. H. Goodfellow, F. F. Kadlubar, and W. W. Weber Pharmacogenetics of the Arylamine N-Acetyltransferases: A Symposium in Honor of Wendell W. Weber Drug Metab. Dispos., April 13, 2001; 28(12): 1425 - 1432. [Abstract] [Full Text]

				A. F. Badawi, E. L. Cavalieri, and E. G. Rogan Effect of chlorinated hydrocarbons on expression of cytochrome P450 1A1, 1A2 and 1B1 and 2- and 4-hydroxylation of 17{beta}-estradiol in female Sprague-Dawley rats Carcinogenesis, August 1, 2000; 21(8): 1593 - 1599. [Abstract] [Full Text] [PDF]

				M. Krajinovic, C. Richer, H. Sinnett, D. Labuda, and D. Sinnett Genetic Polymorphisms of N-Acetyltransferases 1 and 2 and Gene-Gene Interaction in the Susceptibility to Childhood Acute Lymphoblastic Leukemia Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 557 - 562. [Abstract] [Full Text]

				N. M. Probst-Hensch, D. A. Bell, M. A. Watson, P. L. Skipper, S. R. Tannenbaum, K. K. Chan, R. K. Ross, and M. C. Yu N-Acetyltransferase 2 Phenotype but not NAT1*10 Genotype Affects Aminobiphenyl-Hemoglobin Adduct Levels Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 619 - 623. [Abstract] [Full Text]

				D. A. Delker, B. L. Yano, and B. B. Gollapudi Evaluation of Cytotoxicity, Cell Proliferation, and Genotoxicity Induced by p-Cresidine in Hetero- and Nullizygous Transgenic p53 Mice Toxicol. Sci., June 1, 2000; 55(2): 361 - 369. [Abstract] [Full Text] [PDF]

				V. A. Smelt, A. Upton, J. Adjaye, M. A. Payton, S. Boukouvala, N. Johnson, H. J. Mardon, and E. Sim Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos Hum. Mol. Genet., April 12, 2000; 9(7): 1101 - 1107. [Abstract] [Full Text] [PDF]

				A. F. Olshan, M. C. Weissler, M. A. Watson, and D. A. Bell GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 Polymorphisms, Tobacco Use, and the Risk of Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2000; 9(2): 185 - 191. [Abstract] [Full Text]

				M. Peluso, L. Airoldi, C. Magagnotti, L. Fiorini, A. Munnia, A. Hautefeuille, C. Malaveille, and P. Vineis White blood cell DNA adducts and fruit and vegetable consumption in bladder cancer Carcinogenesis, February 1, 2000; 21(2): 183 - 187. [Abstract] [Full Text] [PDF]

				D. W. Hein, M. A. Doll, A. J. Fretland, M. A. Leff, S. J. Webb, G. H. Xiao, U.-S. Devanaboyina, N. A. Nangju, and Y. Feng Molecular Genetics and Epidemiology of the NAT1 and NAT2 Acetylation Polymorphisms Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 29 - 42. [Abstract] [Full Text]

				A. M. Dunning, C. S. Healey, P. D. P. Pharoah, M. D. Teare, B. A. J. Ponder, and D. F. Easton A Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 1999; 8(10): 843 - 854. [Abstract] [Full Text]

				K. Heinimann, R. J. Scott, P. Chappuis, W. Weber, H. Muller, Z. Dobbie, and P. Hutter N-acetyltransferase 2 Influences Cancer Prevalence in hMLH1/hMSH2 Mutation Carriers Cancer Res., July 1, 1999; 59(13): 3038 - 3040. [Abstract] [Full Text] [PDF]

				W. Pfau, F. L. Martin, K. J. Cole, S. Venitt, D. H. Phillips, P. L. Grover, and H. Marquardt Heterocyclic aromatic amines induce DNA strand breaks and cell transformation Carcinogenesis, April 1, 1999; 20(4): 545 - 551. [Abstract] [Full Text] [PDF]

				W. Zheng, A. C. Deitz, D. R. Campbell, W.-Q. Wen, J. R. Cerhan, T. A. Sellers, A. R. Folsom, and D. W. Hein N-Acetyltransferase 1 Genetic Polymorphism, Cigarette Smoking, Well-Done Meat Intake, and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., March 1, 1999; 8(3): 233 - 239. [Abstract] [Full Text] [PDF]

				M. K. Mitchell, B. W. Futscher, and C. A. McQueen Developmental Expression of N-Acetyltransferases in C57BI/6 Mice Drug Metab. Dispos., February 1, 1999; 27(2): 261 - 264. [Abstract] [Full Text]

				M. H. Mostafa, S. A. Sheweita, and P. J. O'Connor Relationship between Schistosomiasis and Bladder Cancer Clin. Microbiol. Rev., January 1, 1999; 12(1): 97 - 111. [Abstract] [Full Text] [PDF]